nam/aidsmap, 14 April 2022 Perceived irrelevance, lack of awareness, problems with access, side effects, negative social impacts, and concerns about lack of STI protection, effectiveness and adherence are the most common reasons for not using PrEP among gay and bisexual men in Australia. This is according to a study recently published in the journal Behavioral Medicine which analysed reasons for...
I’m over the moon!’: patient-perceived outcomes of hepatitis C treatment Davoud Pourmarzi, Andrew Smirnov, Lisa Hall, Gerard FitzGerald, and Tony Rahman Australian Journal of Primary Health 26(4) 319-324 Submitted: 22 January 2020 Accepted: 29 April 2020 Published: 25 June 2020 Abstract Understanding patient-perceived outcomes is crucial for assessing the effectiveness and acceptability of...
“No‐one’s driving this bus” – qualitative analysis of PrEP health promotion for Aboriginal and Torres Strait Islander gay and bisexual men Aust NZ J Public Health, 2019; 43:18-23; doi: 10.1111/1753-6405.12852 Objective: HIV prevention tools such as pre‐exposure prophylaxis require equitable access and uptake to protect all at‐risk populations. This project assessed the perceived barriers to...
ARCSHS, 2018 The knowledge and experience of people who inject drugs (PWID) within peer programs is a vital asset to strategies for the scale-up of DAA treatment among PWID (Brown and Reeders, 2016). This study is focused on translating these “real time” peer insights into resources that support policy and programs to tailor to the needs of communities of people who inject. This tailoring is...
Centre for Social Research in Health, UNSW, 2017 The latest findings from the PrEPARE Project have now been published. The PrEPARE Project is a longitudinal study of Australian gay and bisexual men’s attitudes to biomedical HIV prevention, particularly PrEP and treatment as prevention (TasP). With the unprecedented scaling up of PrEP access in many states over the last few years, we have...
Kirby Institute/UNSW – 21 February 2017
More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.
Read more here
Download report (PDF) here